- Trial phase
- Phase 1
- Time to market
- Unlikely before 2029-2030 at earliest, Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
- Why 4/10
- EDG-15400 is in Phase 1 with no hard dated binary catalyst. Phase 1 top-line data was expected H1 2026 (now closed window) but no formal data PR has been issued; Phase 2 HFpEF trial initiation is planned for H2 2026. Neither event is a sharp binary catalyst. The next real catalyst would be Phase 2 efficacy/safety data, not expected until H1 2027 at the earliest. The drug is also a secondary pipeline asset behind EDG-7500 (HCM, Phase 2/3).
EDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.
Price Chart
Executive Summary
EDG-15400 is an early-stage (Phase 1) cardiac sarcomere modulator from Edgewise Therapeutics (EWTX) for heart failure with preserved ejection fraction (HFpEF), a large and growing market. After selling its muscular dystrophy program (sevasemten) to Servier for up to $2.65B in mid-2026, Edgewise is now a pure cardiovascular company. EDG-15400 is the second-most-advanced pipeline asset behind EDG-7500 (Phase 2/3 for hypertrophic cardiomyopathy). While the mechanism is novel and the market opportunity is substantial (HFpEF represents roughly half of all heart failure), the drug is years away from commercialization with no near-term binary catalyst that would significantly move the stock.
How It Works
EDG-15400 is a small molecule that selectively modulates the cardiac sarcomere, the heart muscle's basic contracting machinery. It is designed to help the heart muscle relax and fill with blood more efficiently (improving "diastolic function") without weakening the heart's pumping force. This targets the root mechanical problem in HFpEF, a type of heart failure where the heart stiffens and cannot relax properly between beats.
Trial Status
A Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose study in healthy adults (NCT07177066) has been enrolling. The study also includes a food-effect/relative bioavailability cohort. Top-line results were expected in H1 2026. A Phase 2 trial in HFpEF patients is planned for H2 2026, with data anticipated in H1 2027. Preclinical data was presented at the ESC Heart Failure 2026 congress showing improved diastolic function in a mini-pig model.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 top-line data disclosure (H1 2026 window, potentially imminent or expected soon)
- Phase 2 trial initiation in HFpEF patients (planned H2 2026)
- Phase 2 HFpEF efficacy/safety data (expected H1 2027)
- Preclinical/translational data presentations at cardiology congresses
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Edgewise Therapeutics, Inc. 8-K EWTX ·Originating report